Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Rational Nanoparticle Design for Efficient Transmucosal CRISPR Delivery in Cystic Fibrosis – “CRISPRGels”

Project description

Treating cystic fibrosis using nanogels

Cystic fibrosis is one of the most serious genetic lung diseases. It is characterised by the build-up of thick mucus in the lungs, leading to infection and breathing difficulties. While advanced modulator therapies have significantly reduced mortality rates, there is still no cure. Supported by the Marie Skłodowska-Curie Actions programme, the CRISPRGels project aims to develop non-viral gene delivery systems for the treatment of cystic fibrosis based on nanogel-mediated controlled release of the CRISPR/Cas9 complex. It will methodically examine the behaviour and interactions of the nanogels in cystic fibrosis patient-derived sputum and bronchial epithelial models. Then it will validate the most effective nanogels on a pre-industrial scale.

Objective

Cystic fibrosis (CF) is the most common genetic lung disease (monogenic autosomal recessive disorder) worldwide and currently there is no cure. The emergence of powerful gene editing tools like CRISPR-Cas (“clustered regularly interspaced short palindromic repeats/associated protein 9”), now provides the opportunity to correct the disease-causing mutations which can potentially cure CF. The present research project proposes the development of core-multishell nanogels (NGs) yielding efficient transmucosal delivery of CRISPR-based gene editing tools which can address the challenges for treatment of CF at European level. This project brings together a talented, highly motivated and young Researcher (Dr. Krishan Kumar) with background in polymer chemistry (phase transition temperatures, understanding structure of colloids, bio-macromolecular interactions) and protein science (structural stability, immobilization, enzymatic activity); and an innovative institute POLYMAT in developing biomedical solutions for treating CF diseases based on nanogels mediated controlled release of CRISPR/Cas9 complex. CRISPRGels will focus on advancing the young researcher’s career through development and manufacture stages of non-viral gene delivery systems facilitating the curative gene editing approaches for treatment of CF patients. The host supervisor Prof. Marcelo Calderón is globally recognized researcher working in area of transmucosal delivery using nanogels (NGs). The behavior and interactions of the NGs will be systematically investigated in CF patient-derived sputum and CF bronchial epithelial models. Most efficient NGs will be validated on pre-industrial scale. Multidisciplinary expertise required for CRISPRGels will be complemented by highly experienced research teams Responsive Polymer Therapeutics Group (RPTG), Translational Organ Models Group (TOMG) and i+Med company.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2022-PF-01

See all projects funded under this call

Coordinator

UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA
Net EU contribution
€ 206 641,20
Address
BARRIO SARRIENA S N
48940 Leioa
Spain
Region
Noreste País Vasco Bizkaia
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (4)